Medicine:AG2037
From HandWiki
AG2037 is a drug that is being studied in the treatment of cancer. This drug belongs to the glycinamide ribonucleotide formyl transferase inhibitors family.[1] This drug can inhibit GARFTase, which is an essential enzyme in the de novo synthesis of purines, a critical process for cell growth.[2]
Treatment with AG2037 has shown that it inhibits mTORC1 activation and robust tumor growth in mice with lung cancer.[3] The treatment has also been studied in controlled experiments on humans.[4]
References
- ↑ "https://www.cancer.gov/publications/dictionaries/cancer-terms/def/ag2037" (in en). 2011-02-02. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/ag2037.
- ↑ Jackman, Ann L.; Leamon, Christopher P. (2011-05-05) (in en). Targeted Drug Strategies for Cancer and Inflammation. Springer Science & Business Media. pp. 22–23. ISBN 978-1-4419-8417-3. https://books.google.com/books?id=vlSZSL-X9S0C&q=AG2037&pg=PA22.
- ↑ Yin, Jie; Ren, Wenkai; Huang, Xingguo; Deng, Jinping; Li, Tiejun; Yin, Yulong (2018-07-30). "Potential Mechanisms Connecting Purine Metabolism and Cancer Therapy". Frontiers in Immunology 9: 1697. doi:10.3389/fimmu.2018.01697. ISSN 1664-3224. PMID 30105018.
- ↑ Robert, F.; Garrett, C.; Dinwoodie, W. R.; Sullivan, D. M.; Bishop, M.; Amantea, M.; Zhang, M.; Reich, S. D. (2004-07-15). "Results of 2 phase I studies of intravenous (iv) pelitrexol (AG2037), a glycinamide ribonucleotide formyltransferase (GARFT) inhibitor, in patients (pts) with solid tumors". Journal of Clinical Oncology 22 (14_suppl): 3075. doi:10.1200/jco.2004.22.90140.3075. ISSN 0732-183X. https://ascopubs.org/doi/abs/10.1200/jco.2004.22.90140.3075.
 |
